WO2002051405A1 - New clinical treatment - Google Patents
New clinical treatment Download PDFInfo
- Publication number
- WO2002051405A1 WO2002051405A1 PCT/SE2001/002919 SE0102919W WO02051405A1 WO 2002051405 A1 WO2002051405 A1 WO 2002051405A1 SE 0102919 W SE0102919 W SE 0102919W WO 02051405 A1 WO02051405 A1 WO 02051405A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- nac
- cell
- neoplasia
- cysteine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title description 35
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 100
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 70
- 230000004069 differentiation Effects 0.000 claims abstract description 31
- 230000035755 proliferation Effects 0.000 claims abstract description 25
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract description 22
- 230000037361 pathway Effects 0.000 claims abstract description 11
- 230000002159 abnormal effect Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 181
- 210000001519 tissue Anatomy 0.000 claims description 24
- 210000004881 tumor cell Anatomy 0.000 claims description 19
- 206010009944 Colon cancer Diseases 0.000 claims description 16
- 230000003902 lesion Effects 0.000 claims description 7
- 208000000058 Anaplasia Diseases 0.000 claims description 5
- 206010054949 Metaplasia Diseases 0.000 claims description 5
- 230000015689 metaplastic ossification Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 230000001185 psoriatic effect Effects 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 33
- 201000011510 cancer Diseases 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 102000011782 Keratins Human genes 0.000 description 8
- 108010076876 Keratins Proteins 0.000 description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000011107 Diacylglycerol Kinase Human genes 0.000 description 7
- 108010062677 Diacylglycerol Kinase Proteins 0.000 description 7
- 102000003923 Protein Kinase C Human genes 0.000 description 7
- 108090000315 Protein Kinase C Proteins 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 201000004681 Psoriasis Diseases 0.000 description 7
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 7
- 210000004292 cytoskeleton Anatomy 0.000 description 7
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- DGAKHGXRMXWHBX-ONEGZZNKSA-N Azoxymethane Chemical compound C\N=[N+](/C)[O-] DGAKHGXRMXWHBX-ONEGZZNKSA-N 0.000 description 5
- 230000010337 G2 phase Effects 0.000 description 5
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000017455 cell-cell adhesion Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000000277 virosome Substances 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000002113 chemopreventative effect Effects 0.000 description 4
- 201000010897 colon adenocarcinoma Diseases 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000030944 contact inhibition Effects 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 3
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000003560 cancer drug Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 230000004736 colon carcinogenesis Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004692 intercellular junction Anatomy 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000026211 mitotic metaphase Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000001316 polygonal cell Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000003518 stress fiber Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- YTPQSLLEROSACP-YUMQZZPRSA-N (2R)-2-acetamido-3-[[(2R)-2-acetamido-2-carboxyethyl]disulfanyl]propanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSSC[C@@H](C(O)=O)NC(C)=O YTPQSLLEROSACP-YUMQZZPRSA-N 0.000 description 1
- PWKSKIMOESPYIA-SCSAIBSYSA-N (2s)-2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](CS)C(O)=O PWKSKIMOESPYIA-SCSAIBSYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YTPQSLLEROSACP-UHFFFAOYSA-N 2-acetamido-3-[(2-acetamido-2-carboxyethyl)disulfanyl]propanoic acid Chemical compound CC(=O)NC(C(O)=O)CSSCC(C(O)=O)NC(C)=O YTPQSLLEROSACP-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102000009875 Ki-67 Antigen Human genes 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 208000007666 Klatskin Tumor Diseases 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010069345 Solid pseudopapillary tumour of the pancreas Diseases 0.000 description 1
- 206010041848 Squamous cell carcinoma of the cervix Diseases 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102100023118 Transcription factor JunD Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003475 colitic effect Effects 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000004188 enterochromaffin-like cell Anatomy 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000002409 gliosarcoma Diseases 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 208000018060 hilar cholangiocarcinoma Diseases 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
- 201000000089 larynx squamous papilloma Diseases 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000014699 malignant epithelioid mesothelioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000004057 myxopapillary ependymoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000030352 pancreatic acinar cell carcinoma Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000005221 pancreatic serous cystadenoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000012237 paracetamol poisoning Diseases 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000003619 porokeratosis Diseases 0.000 description 1
- 230000031339 positive regulation of inflammatory response Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000019140 solid pseudopapillary neoplasm of the pancreas Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000028647 spindle cell neoplasm Diseases 0.000 description 1
- 201000010321 spongiotic dermatitis Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention refers the use of N-acetyl-L- cysteine, or a dimeric form thereof, for the clinical treatment of mammalian neoplasia cells of epithelial origin.
- a tumor, or neoplasm comprises new growth of tissue, in which the multiplication of cells is uncontrolled and progressive. Not all types of abnormal growth are malignant ; those that are not are referred to as benign tumors . In contrast to malignant growths, benign tumors consist of an orderly growth of cells that often are identical to or very closely resemble their normal counterparts.
- a cancer is characterized by uncontrolled multiplication and disorganized growth of the affected cells. Concomitant with their capacity for unrestrained growth, cancer cells and the tissues they constitute lose their normal appearance, as viewed through a microscope, and assume aberrant functions. They are aggressive, invade surrounding tissues, spread to distant sites, and eventually kill the host. In 1994 cancers were responsible for almost one-fourth of all deaths in the United States.
- Tumors are based on the structural and functional properties of their component cells and their biological behavior.
- the cells and tissues of malignant tumors differ from the tissues from which they arise . They exhibit more rapid growth and altered structure and function.
- the properties of malignant tumor cells serve to enhance and support their proliferation and extension throughout the body tissues and organs.
- the cells and tissues of benign tumors tend to grow more slowly and in general closely resemble their normal tissues of origin.
- the structure and function of benign tumor cells are morphologically and functionally indistinguishable from those of normal cells, their growth as a tumor mass is the sole feature indicative of their neoplastic nature .
- a chemotherapy can cure certain forms of cancer, and chemotherapeutic agents have been used, which interfere with the cell cycle during mitosis, i.e. after the G2 phase.
- chemotherapeutic agents have been used, which interfere with the cell cycle during mitosis, i.e. after the G2 phase.
- exogenous substances interfere with the assem- bling/disassembling kinetics of cytoskeletal proteins, e.g. tubulin fibers.
- examples of such substances are for instance the vinca alkaloids (e.g. taxol) .
- cancer drugs are limited in their usefulness .
- One problem is that only a certain proportion of cells is dividing at any one time, and most cancer drugs can destroy only that part of the cell population which undergoes division.
- Another problem is that cancer drugs, apart from damaging cancer cells, also damage normal cells and tissues.
- chemotherapeutic agents which act on cells in different ways, have been used simultaneously or in sequence in various treatment programs .
- N-acetyl-L-cysteine is a thiol-containing compound which prevents or reduces the oxidation.
- NAC sulfydryl residue Due to its antioxidant prop- erties, NAC has also been reported to act as an anti-inflammatory drug by counteracting the action of free radicals, which are byproducts of inflammation.
- NAC has been used in a pharmaceutical composition of doxorubicin for inhibiting the formation of cancer tumors.
- the antioxidant activity of NAC counteracts the cardiotoxicity of doxorubicin.
- N-Acetyl-L-cysteine (L-NAC) and its non-meta- bolically active stereoiso er N-acetyl-D-cysteine (D-NAC) were investigated together with the drugs captopril and dithioerythritol (DTT) in order to assess their effects on cell cycle progression.
- DTT dithioerythritol
- NAC neuropeptide-containing hepatic failure after treatment with paracetamol and related compounds.
- NAC fulminant hepatic failure after treatment with paracetamol and related compounds.
- high doses such as 10 g/day.
- thiol containing compounds such as mercaptoethanol and dithiothreitol .
- the NAC clearance is re- latively rapid.
- N-acetyl-L-cysteine has been used as an anticancer agent for the treatment of myeloma type tumor because it has anticancer activity against myeloma type tumor cells in vitro, a tumor proliferation inhibitory activity being obtained.
- the cell growth and cell renewal in most solid tissues of epithelial origin can be sketched as a duplication of a stem cell into one cell with an end-stage and one cell with a continued growth potential.
- the end-stage cell will then enter the differentiation pathway, in which it performs the diverse tissue functions, and it will have a finite life-span.
- Cells entering the differentiation pathway exhibit a noticeable increase of cell-cell contacts, and the process is also generally indicated as contact inhibition.
- signals for the cells to enter the differentiation end-point originate from the components of cell-cell contacts themselves.
- the cell-cell adhesions are also responsible for the diffusion of signals between cells.
- Cancer cells can be regarded as differentiated cells that have lost this contact inhibition and that continuously proliferate. Thus, cancer cells have lost their ability to respond to differentiation signals. In this respect, instead of having the finite life-span of differentiated cells, cancer cells are eternal.
- the purpose of the present invention is to produce a drug which acts as a therapeutic agent for those diseases which are related to a differentiation malfunctioning in epithelial tissues.
- the method according to the invention has been given the characterizing feature of claim 1.
- N-acetyl-L- cysteine (NAC) and its disulfide dimer, N,N' -diacetyl-L- cystine (di-NAC) are reverting substances which without toxic effects revert the abnormal proliferation of neoplasia cells of epithelial origin back to a normal pathway, including block of proliferation, differentiation and a limited cell life-span.
- Other dimeric forms of N-acetyl-L- cysteine and similar structures e.g. 4, 4 ' - (isopropylidene- dithio) bis [2, 6-di-tert-butylphenol] , also exhibit these effects .
- neoplasia cells means cells which form a neoplasm, i.e. the progressive multiplication of cells under conditions which would not elicit, or cause cessation of, multiplication of normal cells.
- a benign or malign hyperproliferation of cells encompasses metaplasia, i.e. the change in the type of cells in a tissue to a form which is not normal for that tissue; anaplasia, i.e. the loss of differentiation of cells and their orientation to each other; prosoplasia, i.e. the abnormal differentiation of a tissue; and retroplasia, i.e. the degeneration of a tissue or a cell into a more primitive type.
- a reverting action of NAC, or di-NAC involves the regular differentiation of cells in that the generally accepted differentiation in morphological heterogeneity occurs after the G1-G0 phases of the cell cycle and not at the G2 phase .
- N-acetyl-L-cysteine, or a dimeric form thereof according to the invention when a cell is differentiating - instead of dividing any further - the cell exhibits its final normal morphology.
- This reversion of the proliferating tumoral behavior in cells and tissues of epithelial origin is initiated before the new DNA syn- thesis, i.e. before the S phase.
- the cell enters the GO phase (growth zero) , from which the differentiation phase (D phase) starts.
- This phase results in the appropriate morphology, which is due to the syn- thesis and assembling of all components needed which all characterizes the finally differentiated and functionally active cell in the tissue.
- the normal differentiation of neoplasia cells treated with NAC or di-NAC according to the invention can be demon- strated by the increase in cell-cell adhesion structures, the acquisition of several other structures as well as functions, which are typical for a well differentiated cell and differs for each cell type - as will be described below in the Examples - and by the arrest of proliferation.
- Other biochemical differentiation markers are early transcription factors .
- the cell-cell adhesions obtained when for example a tumor is treated with high concentrations of NAC, or di- NAC comprise several adhesive structures between adjacent cells and between cells and the basal extracellular matrix. These are in the microscope seen as tight and adherent junctions as well as desmosomes and gap junctions, each composed by a complex architecture of proteins, often assembled from repetitive sub-units. These contacts span the cell membrane and have extracellular, transmembrane and cytoplasmic sites. The cytoplasmic site of these multi- protein structures is, in turn, connected to the network of cytoskeletal proteins, while the extracellular site is connected either to a neighboring cell or to the basal extracellular matrix.
- NHEK primary normal human epidermal keratinocytes
- CaCo2 human colon carcinoma line
- an effective dose of N-acetyl-L-cysteine, or a dimeric form thereof, which reverts mammalian neoplasia cells of epithelial origin to normal differentiation whereby the abnormal proliferation of such cells is reverted to a normal pathway is according to the invention obtained at a concentration which is higher than that required for the maximum inhibition of proliferation, i.e. absolutely no growth. Accordingly, the inhibition of proliferation does not mean a reversion of neoplasia cells per se, but only if it is accompanied by a differentiation. At these higher doses of NAC and di-NAC the breakdown of most cytoskeletal proteins takes place.
- NAC and di-NAC also prevents the natural restitution of the disrupted cytoskeleton.
- cytoskeleton When the cytoskeleton is fragmented, stronger cell-cell contacts as well as an increased number of cell- cell junctions are obtained, i.e. an increased strength of the interactions between cell junctions and increased number of such junctions. This may be due to the cell-cell junctions being connected to the cytoskeleton network which keeps the junctions at a correct distance for the cell to proliferate. Once this net is broken by a sufficient concentration of NAC or di-NAC, the junctions will collapse and a tighter cell-cell contact will be obtained. This so- called contact inhibition results in a ceased proliferation, and surprisingly, the onset of differentiating, i.e.
- the invention proposes the use of NAC, or di-NAC, for the clinical treatment of neoplasia cells of epithelial origin by inhibiting or stabilizing the corresponding disease, at high or low concentration, respect- ively.
- the type of neoplsia cells is not restrictive for the inventive use, and they can be anaplasia cells, metaplasia cells, prosoplasia cells, or retroplasia cells.
- the inventive use comprises an anticancer therapy, in which the tumor proliferation in tumors of epithelial origin is reverted into the differentiation pathway, including benign and malign hyperproliferation.
- benign tumor cells which can be forced back by NAC, or di-NAC, into a normal differentiation, are epidermal tumor cells and rheumatoidic cells.
- the malign tumors can be lung cancer, breast cancer, prostate cancer, or human colon carcinoma.
- a more comprehensive but non- limiting list of malign cells and tumors which can be reverted back to a normal pathway according to the invention, includes the CNE2 human epithelial tumor cell line, the A431 cell line, 66-kDa She, esophageal cancer cell lines, the HepG2 human tumor cell line, human papillomavirus type 16-containing cancer cell lines, Merkel cell carcinoma cell lines, head and neck carcinoma cell lines, esophageal cancer cell lines, as well as glioblastoma cells, retinoblastoma, human retinoblastoma Y79 cells, hepatocellular carcinoma cells, SH-SY5Y cells, Ehrlich ascites tumor cells, liver epithelial tumor cells, spindle epithelial tumor with thymus-like differentiation (SETTLE) , deciduoid epithelial mesothelioma, epithelial ovarian carcinoma, vulvar intraepithelial neoplasia,
- keratosic skin such as psoriasis and spongiotic dermatitis
- NAC or di-NAC a correct epidermal tropism
- the endothelial cells of diabetic lesions formed in connection with a vascular damage being re-established.
- CK cytokeratins
- VSMC vascular smooth muscle cells
- Tissue samples of normal peripheral and coronary arteries, arteriosclerotic lesions and umbilical cord vessels were evaluated by immunofluorescence microscopy applying antibodies specific for cytokeratins 8 and 18, specific cytokeratin phosphorylation sites, Ki-67-antigen as a proliferation marker and nick end labeling (TUNEL) to detect apoptosis. All samples contained cytokeratin- positive VSMC but diverse phosphorylation patterns. The C-terminal serine 431 of cytokeratin 8 (CK8Ser-431) was phosphorylated in the vast majority of CK-expressing VSMC of coronary artery lesions. Only a subset of these cells demonstrated phosphorylation of CK18Ser-33 or, to an even lesser extent, CK8Ser-73.
- abundant CK phosphorylation in VSMC of arteriosclerotic lesions suggests a specific functional response to cell stress and a possible relation to apoptosis . By definition, all chemotherapeutic agents must be antiproliferative .
- the dose required in order to obtain a reverting effect of NAC, or di-NAC, according to the invention is higher than the dose required for inhibiting proliferation only.
- NAC can be used for treating neoplasia cells in local concentrations from 0.1 to 50 mM, depending on the type of cells treated, on the seriousness of the corresponding disease, and on the stage of the disease.
- the absolute maximum and minimum doses of NAC, or di-NAC, required for a complete block of prolifer- ation depend on the cell type to be treated.
- the minimum dose required in order to accelerate the differentiation of normal keratynocytes is 0.5 mM, and ker- atinocytes completely differentiate at 1 mM.
- the reversion of colon cancer cells is, however, induced at a concen- tration of NAC, or di-NAC, of 1 M, and the colon carcinoma completely differentiate at 5 mM.
- compositions may be prepared which contain effective amounts of NAC, or di-NAC, and a suitable carrier.
- suitable carrier are well known to those skilled in the art.
- NAC or di-NAC may be administered directly or in the form of a composition to a human or animal subject.
- the reverting substances according to the invention can intentionally be brought to a specific site of action by coupling the same to a targeting molecule, e.g. an anti- body, which is directed towards an epitope in the vicinity of the site of action.
- a targeting molecule e.g. an anti- body
- NAC or di-NAC may be bound to antibodies directed towards a specific epithelial tissue in such a way that the reverting activity is targeted towards neoplasia cells of epithelial origin and fused with the same.
- NAC or di-NAC can be supplemented locally as well as systemically and administrated orally, intravenously, intrarticularly, etc., depending on the type of the disease to be treated and on its stage. For example, for epidermal tumors a local application is sufficient. For rheumatoid arthritis, on the other hand, an intrarticular injection is needed. The appropriate route of administration also depends on the type of disease to be treated. For example, NAC has been effectively used for the local therapy of psoriasis as well as for the systemic and local therapy of psoriatic arthritis and of rheumatoid arthritis.
- a treatment with NAC, or di-NAC can be repeated several times with intervals, and the substance can be supplemented continuously as well. Since the tumor cells are not killed by this treatment, the time interval for the evident reversion of the disease depends on the specific life-span of the type of cells treated. With an epidermal tumor for example, having an epidermic cell life-span of about 30 days, an evident decrease of the tumor mass will appear after that time. When psoriasis is treated according to the invention, the symptoms disappear after treatments ranging from few days to 3-4 weeks, and the treatment may have to be repeated after a few months .
- NAC, or di-NAC not only initi- ates differentiating, i.e. tumor reversion in the case of tumor cells, by the growth control of malfunctioning cells which is induced through restored cell-cell contacts. At these concentrations NAC and di-NAC also exhibit the contact inhibition obtained at lower concentrations, which causes the cell to cease to proliferate. Furthermore, in the inventive use NAC and di-NAC also present the antioxidant effect.
- Example 1 Effects of NAC and di -NAC on human colon carcinoma eel 1 s .
- CaCo2 An established cell line of human colon carcinoma cells was used (CaCo2) .
- CaCo2 is a proliferating human colon carcinoma cell line displaying irregular morphology, forming multiple cell layers with scarce microvillous structures and large intercellular spaces.
- the CaCo2 cells were treated with various millimolar concentrations of NAC, ranging from 2 to 10 mM. NAC was added to the culture medium 24 hours after inoculation of the cells. After 3 days of culture in the presence of NAC the cells were analyzed for the following marker para- meters :
- cytoskeleton Disorganization of actin fibers was observed, with the appearance of stress fibers . Relocalization of actin fibers in the upper portion of the cell, sustaining the brush border microvilli, and relocalization of the cytokeratin fibers in the basal portion of cell. Cytokeratin fibers also appeared sparsely fragmented.
- Tubulin expression and polymerization The tubulin expression appeared strongly reduced by the NAC treatment .
- the mitotic spindle was often absent in cells in the mitotic metaphase .
- Proliferation The cell proliferation decreased in a dose-dependent fashion, with a maximum effect at 2 mM NAC .
- Toxicity The cell viability was unaffected by NAC treatment at all doses added. Neither apoptosis nor necrosis was observed.
- a treatment of CaCo2 cells with di-NAC induces morphological and biochemical changes in the cells. For example increased cell thickness, apical-basolateral polarity, increased E-cadherin expression, formation of brush border and tight junctions as well as a decreased proliferation is obtained.
- the treatment with di-NAC was more effective than the treatment with NAC.
- the CaCo2 cells are induced to revert to a differentiation pathway without any detectable toxic side effects. As a consequence of their differentiation the proliferation of the CaCo2 cells is also decreased.
- Example 2 Effects of NAC or di -NAC on human epidermal keratinocytes .
- NHEK Primary normal human epidermal keratinocytes obtained from Clonetics Inc. (San Diego, CA, USA) were cultivated in the medium provided by the supplier. These cells have a limited life-span of about 15 days in culture and undergo a normal differentiation process of epidermal keratinocytes with a final enucleation and exfoliation. After inoculation the cells acquire a polygonal morphology with cell-cell adhesions. The cytoskeleton morphology is quite organized, mainly at the cell borders.
- NHEK cells were treated with various millimolar concentrations of NAC or di-NAC, ranging from 1 to 10 mM. The substances were added to the culture medium 24 hours after inoculation. After 3 days of culture in the presence of 2 mM of NAC or di-NAC the cells were analysed for the following marker parameters :
- cytoskeleton Disorganization of actin fibers was observed, that appeared dispersed all over the cell cytoplasm and several stress fibers appeared. Cytokeratin fibers were dramatically fragmented. The cytoskeleton fragmentation was also monitored by means of elec- trophoresis . Several bands were obtained after the treat- ment, while only one broad band was visible with untreated cells .
- Tubulin expression and polymerization Tubulin expression appeared to be reduced by the treatment. A small reduction in percent of the formation of the mitotic spindle was observed in cells in the mitotic metaphase.
- Toxicity The cell viability was unaffected by NAC treatment at all doses, i.e., up to 10 mM. Neither apoptosis nor necrosis was observed.
- the isolated keratyno- cytes were treated with NAC in the absolute absence of lymphocytes .
- the treatment of NHEK cells with of NAC or di-NAC induced reversion and a 3-4 fold faster differentiation with no toxic side effects.
- the induced differentiation also resulted in that the NHEK proliferation was abolished.
- Example 3 Effects of NAC or di -NAC on psoriasis .
- Psoriasis is a chronic skin disorder which is distinguished by a benign hyperproliferation of cells, a production of cytokines, an accumulation of inflammatory cells, an abnormal keratinization, and an increased vasculariza- tion.
- Example 4 Effects of NAC on large intestinal tumors .
- the large intestinal tumor mass index was likewise significantly lower for the group treated with NAC than for control group (1.93 and 0.04, respectively, p ⁇ 0.001) .
- rats treated with NAC daily no adenocarcinomas were present in the colons.
- NAC reduces the DMH-induced large intestinal tumors in male Sprague-Dawley rats and has a protective effect as seen by the significant inhibition of tumors within the rat colon.
- Example 5 Effects of NAC on colon adenocarcinoma .
- BD-IX rats were divided into four groups: Groups Gl and G2, designated “cancer groups”, were used to study the effects of NAC on the progression of colon cancer, and Groups G3 and G4 , designated “toxicity groups”, were used to study the effects of the treatment on metabolic processes and the parenchyma.
- DHD/K12-PROb cells were injected subcutaneously into the chest of Group Gl and G2 animals . From 1 to 13 weeks after inoculation the animals in Groups G2 and G4 received a weekly injection of NAC. The animals in Groups Gl and G3 received no treatment . In addition, lines of animal and human colon adenocarcinoma cells (DHD/K12-PR0b and HT-29) were used to perform assays in vi tro in order to examine the cytotoxicity of NAC.
- PLC protein kinase C
- TPK tyrosine protein kinase
- DGK diacylglycerol kinase
- NAC significantly inhibited Ca + dependent and independent PKC (P ⁇ 0.01) activities in colonic mucosa and tumors.
- the administration of NAC either significantly suppressed both colonic mucosal and tumor TPK activities (P ⁇ 0.01) .
- rats which had received NAC exhibied a significant increased DGK activity (P ⁇ 0.01) .
- rats treated with NAC had lower levels of 8-isoprostane in the colonic tumors than the control .
- NAC NAC in the chemoprevention of colon cancer involves the modulation of protein kinase C, tyrosine protein kinase and diacyl- glycerol kinase activities by inducing down-regulation of the PKC and TPK activities and up-regulation of the DGK activity.
- these events may in part be responsible for the chemopreventive activity against colon carcinogenesis .
- NAC will augment the regulation of PKC, TPK and DGK activities in the colon.
- Example 7 Effects of NAC or di -NAC on oral kera- tinocytic tumors and their metasta tic dissemina tion .
- NAC or di-NAC The effects of NAC or di-NAC on the metastatic capacity of clonal populations of 4NQO-induced rat malignant oral keratinocytes were examined after orthotopic trans- plantation to athymic mice.
- Polygonal cells and spindle cells formed well-differentiated squamous cell carcinomas (keratin positive and vimentin negative) and undifferenti- ated spindle cell tumors (keratin negative and vimentin positive) , respectively, in all animals at the site of inoculation (floor of mouth) .
- TGF- ⁇ l trans- forming growth factor ⁇ l
- NAC trans-forming growth factor ⁇ l
- di-NAC trans- forming growth factor ⁇ l
- the results suggest that the TGF- ⁇ l induced by NAC, or di-NAC, may act as a tumor suppressor in this cell type.
- the clones of polygonal cells were markedly inhibited by exogenous NAC, and the spindle cells were inhibited as well.
- the results also suggest that differentiated rat malignant oral keratinocytes are less aggressive when treated with NAC or di-NAC, and they have a decreased potential to metastasise than their untreated counterparts. Similar findings were seen in the undifferentiated spindle cell counterparts.
- the contribution of TGF- ⁇ and its receptor profile may partly account for the finding that NAC or a dimeric form thereof reduces malignant oral keratinocytic tumors and their metastatic dissemination.
- Influenza virosomes can be targeted towards ovarian carcinoma cells (OVCAR-3) with preservation of fusion activity. This is achieved by incorporating poly (ethylene glycol) (PEG) - derivatized lipids into the virosome membrane (Mastro- battista E, Schoen P, Wilschut J, Crommelin DJ, Storm G. FEBS Lett 2001 Nov 30 ; 509 (1) : 71-76) .
- PEG poly (ethylene glycol)
- Fab ' -fragments of the monoclonal antibody (mAb) 323/A3 were coupled to the distal ends of PEG lipids.
- This PEG layer serves as shield to prevent interaction of viral hemagglutinin with ubiquit- ous sialic acid residues and as spatial anchor for antibody attachment.
- a specific binding of virosomes OVCAR-3 cells is obtained.
- the antibody-redirected virosomes fuse with membranes of OVCAR-3 cells in a pH- dependent fashion.
- Peroxisome proliferator-activated receptors are ligand-activated transcription factors belonging to the nuclear receptor family (Chinetti G. , Fruchart J.-C,
- PPAR- ⁇ is highly expressed in tissues such as liver, muscle, kidney and heart, where it stimulates the ⁇ -oxidative degradation of fatty acids.
- PPAR- ⁇ is predominantly expressed in intestine and adipose tissue.
- PPAR- ⁇ triggers adipocyte differentiation and promotes lipid storage.
- the hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPAR- ⁇ and PPAR- ⁇ , respectively.
- fatty acids and eicosanoids are natural PPAR ligands : PPAR- ⁇ is activated by leukotriene B4 , whereas prostaglandin J2 is a PPAR- ⁇ ligand.
- PPAR- ⁇ deficient mice display a prolonged response to inflammatory stimuli.
- PPAR activators hsave also been shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNF- ⁇ and metalloproteases) by negatively interfering with the NF- ⁇ , STAT and AP-1 signalling pathways.
- inflammatory response genes such as IL-2, IL-6, IL-8, TNF- ⁇ and metalloproteases
- PPAR activators exert these anti-inflammatory activities in different immuno- logical and vascular wall cell types, such as monocyte/macrophages, endothelial, epithelial and smooth muscle cells, in which PPARs are expressed.
- Effective concentrations of NAC thus exhibit not only a metabolic but also an inflammation control by inhibiting PPARs.
- inflammation-related diseases such as atherosclerosis and inflammatory bowel disease.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0116523-2A BR0116523A (en) | 2000-12-27 | 2001-12-27 | Use of n-acetyl-1-cysteine, or a dimeric form thereof, for the clinical treatment of mammalian neoplastic cells of epithelial origin |
CA002432570A CA2432570A1 (en) | 2000-12-27 | 2001-12-27 | New clinical treatment |
US10/450,724 US20040097521A1 (en) | 2000-12-27 | 2001-12-27 | Clinical treatment |
EP01272445A EP1345600A1 (en) | 2000-12-27 | 2001-12-27 | New clinical treatment |
JP2002552550A JP2004516305A (en) | 2000-12-27 | 2001-12-27 | New clinical treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0004867-8 | 2000-12-27 | ||
SE0004867A SE518784C2 (en) | 2000-12-27 | 2000-12-27 | "N-Acetyl-L-Cysteine with Compositions for the Treatment of Neoplasms" |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002051405A1 true WO2002051405A1 (en) | 2002-07-04 |
Family
ID=20282446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2001/002919 WO2002051405A1 (en) | 2000-12-27 | 2001-12-27 | New clinical treatment |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040097521A1 (en) |
EP (1) | EP1345600A1 (en) |
JP (1) | JP2004516305A (en) |
CN (1) | CN1204884C (en) |
BR (1) | BR0116523A (en) |
CA (1) | CA2432570A1 (en) |
RU (1) | RU2003123106A (en) |
SE (1) | SE518784C2 (en) |
WO (1) | WO2002051405A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090227676A1 (en) * | 2003-10-16 | 2009-09-10 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
WO2012130609A1 (en) | 2011-04-01 | 2012-10-04 | Iasomai Ab | New combination comprising n-acetyl-l-cysteine and its use |
WO2024052553A1 (en) | 2022-09-08 | 2024-03-14 | Iasomai Ab | Combination comprising n-acetyl-l-cysteine, selenomethionine and melatonine for treatment of anxiety disorder |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10160796A1 (en) * | 2001-12-11 | 2003-06-26 | Wulf Droege | Use of cysteine or its derivative for increasing tissue oxygen supply, respiratory activity and/or plasma erythropoietin levels, e.g. in cancer or cardio-pulmonary disease patients |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0840888A (en) * | 1994-07-28 | 1996-02-13 | Ajinomoto Co Inc | Antitumor agent against myeloma-based tumor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3343141A1 (en) * | 1983-11-29 | 1985-06-05 | Hermann P.T. 7400 Tübingen Ammon | USE OF CYSTEIN DERIVATIVES OR THEIR SALTS, TO INCREASE THE INSULIN SECRETION OF THE LANGERHANS ISLANDS OF THE LATIVAL GLANCE |
IT1170268B (en) * | 1983-12-21 | 1987-06-03 | Zambon Spa | USE OF ACETYLCISTEIN TO REDUCE THE INCREASE IN THE PROLIEFERATION OF THE BASAL CELLS OF THE RESPIRATORY THRACHEO-BRONCHIAL EPITHELIUM INDUCED BY TOBACCO SMOKE IN MAMMALS |
IL98310A (en) * | 1990-06-08 | 1996-08-04 | Astra Ab | Pharmaceutical compositions comprising cystine derivatives |
SE9103572D0 (en) * | 1991-11-29 | 1991-11-29 | Astra Ab | ORGANIC SALTS OF N, N'-DIACETYL CYSTINE |
JPH06279397A (en) * | 1993-03-31 | 1994-10-04 | Eisai Co Ltd | Improver for amino acid-based peripehral nerve disorder |
US5733535A (en) * | 1995-10-25 | 1998-03-31 | The Procter & Gamble Co. | Topical compositions containing N-acetylcysteine and odor masking materials |
AU6436998A (en) * | 1997-02-20 | 1998-09-09 | Yale University | Therapeutic uses for antioxidants |
DE19747546A1 (en) * | 1997-10-07 | 1999-04-08 | Thomas Dr Med Zollner | Use of systemically administrable water-soluble antioxidant |
JP2000309532A (en) * | 1999-04-28 | 2000-11-07 | Ajinomoto Co Inc | Antirheumatic agent |
-
2000
- 2000-12-27 SE SE0004867A patent/SE518784C2/en not_active IP Right Cessation
-
2001
- 2001-12-27 CA CA002432570A patent/CA2432570A1/en not_active Abandoned
- 2001-12-27 BR BR0116523-2A patent/BR0116523A/en not_active IP Right Cessation
- 2001-12-27 EP EP01272445A patent/EP1345600A1/en not_active Withdrawn
- 2001-12-27 US US10/450,724 patent/US20040097521A1/en not_active Abandoned
- 2001-12-27 CN CNB018215076A patent/CN1204884C/en not_active Expired - Fee Related
- 2001-12-27 WO PCT/SE2001/002919 patent/WO2002051405A1/en not_active Application Discontinuation
- 2001-12-27 JP JP2002552550A patent/JP2004516305A/en active Pending
- 2001-12-27 RU RU2003123106/15A patent/RU2003123106A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0840888A (en) * | 1994-07-28 | 1996-02-13 | Ajinomoto Co Inc | Antitumor agent against myeloma-based tumor |
Non-Patent Citations (3)
Title |
---|
D.J. GRDINA ET AL.: "Effects of thiols on topoisomerase-II alpha activity and cell cycle progression", CELL. PROLIF., vol. 31, 1998, pages 217 - 229, XP002950272 * |
NICO VAN ZANDWIJK ET AL.: "N-acetylcysteine (NAC) and glutathione (GSH): Antioxidant and chemopreventive properties, with special refenrece to lung cancer", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 22, no. SUPPL., 1995, pages 24 - 32, XP002950273 * |
PATENT ABSTRACTS OF JAPAN * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090227676A1 (en) * | 2003-10-16 | 2009-09-10 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
US8222008B2 (en) * | 2003-10-16 | 2012-07-17 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
WO2012130609A1 (en) | 2011-04-01 | 2012-10-04 | Iasomai Ab | New combination comprising n-acetyl-l-cysteine and its use |
US10300038B2 (en) | 2011-04-01 | 2019-05-28 | Iasomai Ab | Combination comprising N-acetyl-L-cysteine and its use |
US11207287B2 (en) | 2011-04-01 | 2021-12-28 | Iasomai Ab | Combination comprising N-acetyl-L-cysteine and its use |
WO2024052553A1 (en) | 2022-09-08 | 2024-03-14 | Iasomai Ab | Combination comprising n-acetyl-l-cysteine, selenomethionine and melatonine for treatment of anxiety disorder |
Also Published As
Publication number | Publication date |
---|---|
BR0116523A (en) | 2004-02-03 |
CN1204884C (en) | 2005-06-08 |
CN1482906A (en) | 2004-03-17 |
SE0004867D0 (en) | 2000-12-27 |
US20040097521A1 (en) | 2004-05-20 |
RU2003123106A (en) | 2005-01-20 |
SE0004867L (en) | 2002-06-28 |
JP2004516305A (en) | 2004-06-03 |
SE518784C2 (en) | 2002-11-19 |
EP1345600A1 (en) | 2003-09-24 |
CA2432570A1 (en) | 2002-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity | |
Dianzani et al. | Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model | |
Chytil et al. | Mediation of retinoic acid-induced growth and anti-tumour activity | |
KR100586754B1 (en) | Inhibition of Lipoprotein Oxidation | |
Li et al. | Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling | |
Yang et al. | Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies | |
RU2283105C2 (en) | Saturated acid analogs for cancer treatment | |
US10729669B2 (en) | Compositions and methods for treating cancer | |
Zhou et al. | Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro | |
Wang et al. | Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system | |
Failla et al. | Increased bioavailability of ubiquinol compared to that of ubiquinone is due to more efficient micellarization during digestion and greater GSH-dependent uptake and basolateral secretion by Caco-2 cells | |
Chen et al. | P27/Kip1 is responsible for magnolol-induced U373 apoptosis in vitro and in vivo | |
RU2204388C2 (en) | Ibuprofen thioether as inhibitor depending upon nf-kb formation of inflammation and pain mediators | |
Basak et al. | Malabaricone C attenuates nonsteroidal anti-inflammatory drug-induced gastric ulceration by decreasing oxidative/nitrative stress and inflammation and promoting angiogenic autohealing | |
Jiang et al. | Inhibiting hypoxia and chemotherapy-induced cancer cell metastasis under a valid therapeutic effect by an assistance of biomimetic oxygen delivery | |
US20040097521A1 (en) | Clinical treatment | |
Bai et al. | Natural compound allicin containing thiosulfinate moieties as transmembrane protein 16A (TMEM16A) Ion channel inhibitor for food adjuvant therapy of lung cancer | |
US20020022022A1 (en) | Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors | |
Huguenin et al. | Nitrosulindac (NCX 1102): a new nitric oxide‐donating non‐steroidal anti‐inflammatory drug (NO‐NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines | |
Guo et al. | Green pea (Pisum sativum L.) Hull polyphenol extract alleviates NAFLD through VB6/TLR4/NF-κB and PPAR pathways | |
Feng et al. | Biomimetic grapefruit-derived extracellular vesicles for safe and targeted delivery of sodium thiosulfate against vascular calcification | |
AU2002216600A1 (en) | New clinical treatment | |
Kimura et al. | Acyclic retinoid NIK-333 accelerates liver regeneration and lowers serum transaminase activities in 70% partially hepatectomized rats, in vivo | |
Zhu et al. | Fatostatin promotes anti-tumor immunity by reducing SREBP2 mediated cholesterol metabolism in tumor-infiltrating T lymphocytes | |
Hetrick et al. | Watermelon powder supplementation reduces colonic cell proliferation and aberrant crypt foci by upregulating p21Waf1/Cip1 expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001272445 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2432570 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002216600 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018215076 Country of ref document: CN Ref document number: 2002552550 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 01090/DELNP/2003 Country of ref document: IN Ref document number: 1090/DELNP/2003 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001272445 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10450724 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 412/DELNP/2004 Country of ref document: IN |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001272445 Country of ref document: EP |